# Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

> **NCT00002956** · PHASE1 · WITHDRAWN · sponsor: **University of Alabama at Birmingham**

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

## Key facts

- **NCT ID:** NCT00002956
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 1996-11
- **Primary completion:** 2002-02
- **Final completion:** 2002-02
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002956, "Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00002956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*